These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32075397)

  • 1. Biliary tract cancer and genomic alterations in homologous recombinant deficiency: exploiting synthetic lethality with PARP inhibitors.
    Ahn DH; Bekaii-Saab T
    Chin Clin Oncol; 2020 Feb; 9(1):6. PubMed ID: 32075397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
    Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
    Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer.
    Seo HR; Nam AR; Bang JH; Oh KS; Kim JM; Yoon J; Kim TY; Oh DY
    Cancer Res Treat; 2022 Apr; 54(2):541-553. PubMed ID: 34352995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer.
    Berchuck JE; Facchinetti F; DiToro DF; Baiev I; Majeed U; Reyes S; Chen C; Zhang K; Sharman R; Uson Junior PLS; Maurer J; Shroff RT; Pritchard CC; Wu MJ; Catenacci DVT; Javle M; Friboulet L; Hollebecque A; Bardeesy N; Zhu AX; Lennerz JK; Tan B; Borad M; Parikh AR; Kiedrowski LA; Kelley RK; Mody K; Juric D; Goyal L
    Ann Oncol; 2022 Dec; 33(12):1269-1283. PubMed ID: 36089135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations.
    Wardell CP; Fujita M; Yamada T; Simbolo M; Fassan M; Karlic R; Polak P; Kim J; Hatanaka Y; Maejima K; Lawlor RT; Nakanishi Y; Mitsuhashi T; Fujimoto A; Furuta M; Ruzzenente A; Conci S; Oosawa A; Sasaki-Oku A; Nakano K; Tanaka H; Yamamoto Y; Michiaki K; Kawakami Y; Aikata H; Ueno M; Hayami S; Gotoh K; Ariizumi SI; Yamamoto M; Yamaue H; Chayama K; Miyano S; Getz G; Scarpa A; Hirano S; Nakamura T; Nakagawa H
    J Hepatol; 2018 May; 68(5):959-969. PubMed ID: 29360550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers.
    Tang TY; Nichetti F; Kaplan B; Lonardi S; Pietrantonio F; Salvatore L; Vivaldi C; Rimassa L; de Braud F; Rizzato MD; Pavlick D; Chu R; Danner De Armas A; Sharaf R; Sokol E; Rodon Ahnert J; Ross JS; Javle M; Niger M
    Clin Cancer Res; 2023 Dec; 29(23):4853-4862. PubMed ID: 37773629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies.
    Mehta R; Wood AC; Yu J; Kim R
    Expert Opin Investig Drugs; 2021 Apr; 30(4):451-461. PubMed ID: 33660569
    [No Abstract]   [Full Text] [Related]  

  • 8. PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
    Ricci AD; Rizzo A; Bonucci C; Tober N; Palloni A; Mollica V; Maggio I; Deserti M; Tavolari S; Brandi G
    Medicines (Basel); 2020 Aug; 7(9):. PubMed ID: 32878011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings.
    Maynard H; Stadler ZK; Berger MF; Solit DB; Ly M; Lowery MA; Mandelker D; Zhang L; Jordan E; El Dika I; Kemel Y; Ladanyi M; Robson ME; O'Reilly EM; Abou-Alfa GK
    Cancer; 2020 Jan; 126(9):1995-2002. PubMed ID: 32012241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Implications of BRCA Mutations in Advanced Biliary Tract Cancer.
    Kim H; Kim JY; Park KU
    Oncology; 2023; 101(1):41-48. PubMed ID: 36257294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.
    Mody K; Jain P; El-Refai SM; Azad NS; Zabransky DJ; Baretti M; Shroff RT; Kelley RK; El-Khouiery AB; Hockenberry AJ; Lau D; Lesinski GB; Yarchoan M
    JCO Precis Oncol; 2022 Jun; 6():e2100510. PubMed ID: 35675577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers.
    Belli C; Boscolo Bielo L; Repetto M; Crimini E; Scalia R; Diana A; Orefice J; Ascione L; Pellizzari G; Fusco N; Barberis M; Daniele B; Guerini-Rocco E; Curigliano G
    Oncologist; 2024 Aug; 29(8):707-715. PubMed ID: 38823036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer.
    Okawa Y; Iwasaki Y; Johnson TA; Ebata N; Inai C; Endo M; Maejima K; Sasagawa S; Fujita M; Matsuda K; Murakami Y; Nakamura T; Hirano S; Momozawa Y; Nakagawa H
    J Hepatol; 2023 Feb; 78(2):333-342. PubMed ID: 36243179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes.
    Chen X; Wang D; Liu J; Qiu J; Zhou J; Ying J; Shi Y; Wang Z; Lou H; Cui J; Zhang J; Liu Y; Zhao F; Pan L; Zhao J; Zhu D; Chen S; Li X; Li X; Zhu L; Shao Y; Shu Y
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer.
    Yu H; Xu Y; Gao W; Li M; He J; Deng X; Xing W
    Front Oncol; 2022; 12():930611. PubMed ID: 36072793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
    Cook SA; Tinker AV
    BioDrugs; 2019 Jun; 33(3):255-273. PubMed ID: 30895466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translating cancer genomics for precision oncology in biliary tract cancers.
    Haber PK; Sia D
    Discov Med; 2019; 28(155):255-265. PubMed ID: 32053766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.
    Takagi M; Yoshida M; Nemoto Y; Tamaichi H; Tsuchida R; Seki M; Uryu K; Nishii R; Miyamoto S; Saito M; Hanada R; Kaneko H; Miyano S; Kataoka K; Yoshida K; Ohira M; Hayashi Y; Nakagawara A; Ogawa S; Mizutani S; Takita J
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
    Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.